{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:48:57Z","timestamp":1770223737116,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ackdjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1053\/j.ackd.2017.05.009","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T21:33:16Z","timestamp":1501623196000},"page":"253-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dual Organ Duel: The Hepatorenal Axis"],"prefix":"10.1053","volume":"24","author":[{"given":"Ladan","family":"Golestaneh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Neugarten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2017.05.009_bib1","series-title":"Your Liver","year":"2016"},{"issue":"Suppl. 3","key":"10.1053\/j.ackd.2017.05.009_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2036.2004.02112.x","article-title":"Review article: pathogenesis and pathophysiology of hepatorenal syndrome\u2014is there scope for prevention?","volume":"20","author":"Moller","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1053\/j.ackd.2017.05.009_bib3","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.ajkd.2011.12.032","article-title":"Hepatorenal syndrome: a severe but treatable cause of kidney failure in cirrhosis","volume":"59","author":"Fagundes","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ackd.2017.05.009_bib4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1053\/j.ajkd.2015.09.013","article-title":"Pathogenesis of hepatorenal syndrome: implications for therapy","volume":"67","author":"Durand","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ackd.2017.05.009_bib5","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1378\/chest.14-1925","article-title":"Hepatorenal disorders","volume":"148","author":"Al-Khafaji","year":"2015","journal-title":"Chest"},{"key":"10.1053\/j.ackd.2017.05.009_bib6","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2013.04.036","article-title":"A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis","volume":"59","author":"Fagundes","year":"2013","journal-title":"J Hepatol"},{"issue":"1","key":"10.1053\/j.ackd.2017.05.009_bib7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/ki.2013.78","article-title":"Bile cast nephropathy is a common pathologic inding for kidney injury associated with severe liver dysfunction","volume":"84","author":"van Slambrouck","year":"2013","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2017.05.009_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/jlts.2002.31516","article-title":"Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation","volume":"8","author":"Davis","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1053\/j.ackd.2017.05.009_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/lt.23384","article-title":"Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome","volume":"18","author":"Nadim","year":"2011","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1053\/j.ackd.2017.05.009_bib10","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1478-3231.2009.02182.x","article-title":"The spectrum of renal lesions in patients with\u00a0cirrhosis: a clinicopathological study","volume":"30","author":"Trawale","year":"2010","journal-title":"Liver Int"},{"key":"10.1053\/j.ackd.2017.05.009_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ki.2014.338","article-title":"Renal dysfunction in cirrhosis is not just a vasomotor nephropathy","volume":"87","author":"Adebayo","year":"2015","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2017.05.009_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12876-016-0434-3","article-title":"Effect of coexisting diabetes mellitus and chronic kidney disease on mortality of cirrhotic patients with esophageal variceal bleeding","volume":"16","author":"Lung","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"10.1053\/j.ackd.2017.05.009_bib13","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2215\/CJN.09430913","article-title":"Urinary biomarkers and progression of AKI in patients with cirrhosis","volume":"9","author":"Belcher","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2017.05.009_bib14","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised Consensus Recommendations of the International Club of Ascites","volume":"62","author":"Angeli","year":"2015","journal-title":"J Hepatol"},{"key":"10.1053\/j.ackd.2017.05.009_bib15","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/hep.21920","article-title":"Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure","volume":"46","author":"Thabut","year":"2007","journal-title":"Hepatology"},{"issue":"3","key":"10.1053\/j.ackd.2017.05.009_bib16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/MAJ.0000000000000268","article-title":"New insight into volume overload and hepatorenal syndrome in cirrhosis, \u201cthe hepatorenal reflex hypothesis\u201d","volume":"348","author":"Rzouq","year":"2014","journal-title":"Am J Med Sci"},{"key":"10.1053\/j.ackd.2017.05.009_bib17","first-page":"R390","article-title":"Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nerve activity","volume":"238","author":"Kostreva","year":"1980","journal-title":"Am J Phys"},{"key":"10.1053\/j.ackd.2017.05.009_bib18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2170\/jjphysiol.36.441","article-title":"Reflex renal vasoconstriction on portal vein distension","volume":"36","author":"Koyama","year":"1986","journal-title":"Jpn J Physiol"},{"issue":"2","key":"10.1053\/j.ackd.2017.05.009_bib19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/hep.1840200215","article-title":"Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease","volume":"20","author":"Platt","year":"1994","journal-title":"Hepatology"},{"key":"10.1053\/j.ackd.2017.05.009_bib20","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/qjmed\/95.12.827","article-title":"Hyperdynamic circulation in liver cirrhosis: not peripheral vasodilatation but \u2018splanchnic steal\u2019","volume":"95","author":"Newby","year":"2002","journal-title":"QJM"},{"key":"10.1053\/j.ackd.2017.05.009_bib21","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","article-title":"Nonselective \u03b2 blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"146","author":"Mandorfer","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1053\/j.ackd.2017.05.009_bib22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00134-008-1253-y","article-title":"Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites","volume":"35","author":"Umgelter","year":"2009","journal-title":"Intensive Care Med"},{"issue":"11","key":"10.1053\/j.ackd.2017.05.009_bib23","first-page":"2523","article-title":"Hepatorenal syndrome: insights into the mechanisms of intra-abdominal hypertension","volume":"6","author":"Chang","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1053\/j.ackd.2017.05.009_bib24","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.25854","article-title":"Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis","volume":"56","author":"Munoz","year":"2012","journal-title":"Hepatology"},{"key":"10.1053\/j.ackd.2017.05.009_bib25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1053\/jhep.2003.50038","article-title":"Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement","volume":"37","author":"Albillos","year":"2003","journal-title":"Hepatology"},{"key":"10.1053\/j.ackd.2017.05.009_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-1-4684-8240-9_22","article-title":"Role of endotoxin in hepatorenal syndrome","volume":"212","author":"Passavanti","year":"1987","journal-title":"Adv Exp Med Biol"},{"key":"10.1053\/j.ackd.2017.05.009_bib27","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/hep.24253","article-title":"Paneth cell-derived interleukin-17A causes multiorgan dysfunction after hepatic ischemia and reperfusion injury","volume":"53","author":"Park","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.ackd.2017.05.009_bib28","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/liv.12047","article-title":"Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis","volume":"33","author":"Shah","year":"2013","journal-title":"Liver Int"},{"key":"10.1053\/j.ackd.2017.05.009_bib29","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jhep.2003.12.010","article-title":"Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascetic alcoholic cirrhosis: amelioration with norfloxacin","volume":"40","author":"Albillos","year":"2004","journal-title":"J Hepatol"},{"key":"10.1053\/j.ackd.2017.05.009_bib30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.cgh.2016.09.156","article-title":"Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic liver failure","volume":"15","author":"Huelin","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1053\/j.ackd.2017.05.009_bib31","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/jgh.13002","article-title":"Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: a retrospective cohort study","volume":"30","author":"Busics","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"10.1053\/j.ackd.2017.05.009_bib32","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s00134-007-0760-6","article-title":"RIFLE classification can predict short-term prognosis in critically ill cirrhotic patients","volume":"33","author":"Jenq","year":"2007","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1053\/j.ackd.2017.05.009_bib33","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.1111\/j.1399-0012.2011.01542.x","article-title":"Renal histological lesions and outcome in liver transplant recipients","volume":"26","author":"Tsapenko","year":"2012","journal-title":"Clin Transplant"},{"key":"10.1053\/j.ackd.2017.05.009_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.phrs.2016.08.027","article-title":"Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: implications for its safety profile","volume":"113","author":"Colson","year":"2016","journal-title":"Pharm Res"},{"key":"10.1053\/j.ackd.2017.05.009_bib35","first-page":"CD005162","article-title":"Terlipressin for hepatorenal syndrome","volume":"9","author":"Gluud","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.ackd.2017.05.009_bib36","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1053\/j.ackd.2017.05.009_bib37","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1172\/JCI105679","article-title":"Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion","volume":"46","author":"Tristani","year":"1967","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1053\/j.ackd.2017.05.009_bib38","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/lt.24210","article-title":"Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: effects on kidney function and transplantation outcomes","volume":"21","author":"Rodriguez","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1053\/j.ackd.2017.05.009_bib39","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/apt.12025","article-title":"Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan, and lixivaptan) in cirrhosis with ascites or hyponatremia","volume":"36","author":"Dahl","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1053\/j.ackd.2017.05.009_bib40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/toxsci\/kfw193","article-title":"Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors","volume":"155","author":"Woodhead","year":"2017","journal-title":"Toxicol Sci"},{"issue":"1","key":"10.1053\/j.ackd.2017.05.009_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1517\/17425255.2013.835802","article-title":"The effects of acute renal failure on drug metabolism","volume":"10","author":"Philips","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"10.1053\/j.ackd.2017.05.009_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/cc7093","article-title":"Clinical review: Drug Metabolism and nonrenal clearance in acute kidney injury","volume":"12","author":"Vilay","year":"2008","journal-title":"Crit Care"},{"key":"10.1053\/j.ackd.2017.05.009_bib43","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990-2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2017.05.009_bib44","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infections and severe renal impairment or end stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.ackd.2017.05.009_bib45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2215\/CJN.03710708","article-title":"Hepatitis C infection and chronic renal disease","volume":"4","author":"Perico","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2017.05.009_bib46","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3748\/wjg.v21.i2.408","article-title":"Management of hepatitis C in patients with chronic kidney disease","volume":"21","author":"Calvalho-Filho","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.ackd.2017.05.009_bib47","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"key":"10.1053\/j.ackd.2017.05.009_bib48","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-na\u00efve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.ackd.2017.05.009_bib49","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2014.08.052","article-title":"Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET","volume":"62","author":"Gordon","year":"2015","journal-title":"J Hepatol"},{"issue":"6","key":"10.1053\/j.ackd.2017.05.009_bib50","first-page":"763","article-title":"Safety, efficacy and tolerability of half dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease","volume":"63","author":"Bhamidimarri","year":"2015","journal-title":"J Hepatol"},{"issue":"4","key":"10.1053\/j.ackd.2017.05.009_bib51","first-page":"651","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis","volume":"151","author":"Kwo","year":"2017","journal-title":"J Hepatol"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559517300861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559517300861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T16:50:36Z","timestamp":1535561436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559517300861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1548559517300861"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2017.05.009","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual Organ Duel: The Hepatorenal Axis","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2017.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}